Angiopoietin-2 predicts all-cause mortality in male but not female end-stage kidney disease patients on hemodialysis

• Verfasst von: Chu, Chang [VerfasserIn]
• Verfasst von: Chen, Xin [VerfasserIn]
• Verfasst von: Hasan, Ahmed A [VerfasserIn]
• Verfasst von: Szakallova, Angelika [VerfasserIn]
• Verfasst von: Krämer, Bernhard [VerfasserIn]
• Verfasst von: Tepel, Martin [VerfasserIn]
• Verfasst von: Hocher, Berthold [VerfasserIn]
• Titel: Angiopoietin-2 predicts all-cause mortality in male but not female end-stage kidney disease patients on hemodialysis
• Verf.angabe: Chang Chu, Xin Chen, Ahmed A Hasan, Angelika Szakallova, Bernhard K Krämer, Martin Tepel and Berthold Hocher
• Jahr: 2022
• Umfang: 9 S.
• Fussnoten: Gesehen am 09.01.2024
• Titel Quelle: Enthalten in: Nephrology, dialysis, transplantation
• Ort Quelle: Oxford : Oxford Univ. Press, 1986
• Jahr Quelle: 2022
• Band/Heft Quelle: 37(2022), 7 vom: Juli, Seite 1348-1356
• ISSN Quelle: 1460-2385
• DOI: doi:10.1093/ndt/gfab332
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1877492884

Abstract

Angiopoietin-2 (Ang-2) plays a pivotal role in pathological vascular remodeling and angiogenesis. Both vascular mechanisms are active in patients with end-stage renal disease (ESRD) and may contribute to the high mortality in these patients. The aim of this multicenter prospective cohort study was to investigate baseline serum Ang-2 concentrations in ESRD patients on hemodialysis (HD) for their ability to predict all-cause mortality.We conducted a prospective cohort study in 340 stable HD patients from different chronic dialysis centers in Berlin, Germany. The primary endpoint was all-cause mortality during a 5-year follow-up period. Blood samples and clinical data were collected at baseline. Serum Ang-2 was measured with a validated enzyme-linked immunosorbent assay (Biomedica, Vienna, Austria).A total of 313 HD patients (206 men and 107 women) were finally included in the study. Receiver operating characteristic (ROC) analysis of Ang-2 concentrations yielded an area under the curve (AUC) of 0.65 (P < 0.0001) for predicting all-cause mortality in the entire study population and was used to determine the optimal cut-off (111.0 pmol/L) for all-cause mortality. Kaplan-Meier survival analysis indicated that male but not female end-stage kidney disease patients on HD with higher Ang-2 concentrations had a significantly lower survival (log-rank test, P < 0.0001 and P = 0.380 for male and female patients, respectively). Multivariable Cox regression analyses adjusted for age, comorbidity, smoking, dialysis vintage, serum creatinine, hemoglobin, C-reactive protein, serum albumin, intact parathyroid hormone (iPTH), low-density lipoprotein (LDL) and Kt/V likewise indicated that elevated Ang-2 concentrations are associated with all-cause mortality in male {hazard ratio [HR] 3.294 [95% confidence interval (CI) 1.768-6.138]; P = 0.0002} but not in female end-stage kidney disease patients on HD [HR 1.084 (95% CI 0.476-2.467); P = 0.847].Ang-2 at baseline is independently associated with all-cause mortality in male ESRD patients on HD.